Gilead hikes full-year sales outlook, quarterly HIV sales rise 18%
Gilead Sciences raised its full-year sales forecast to $31B-$31.3B, up from $30.1B-$30.4B, citing a 13% rise in Q3 sales. HIV drug sales increased 18% to $6.2B, with Biktarvy sales up 10% to $4.1B. Q3 adjusted earnings were $2.55 per share on revenue of $8.3B, exceeding estimates. The company also reported a wider expected annual loss due to deal-related charges.
How this was made
The 30-second read
Why it matters
The key trade-off is an upward full-year product sales guide versus a worse full-year adjusted loss per share outlook driven by substantial deal-related charges. HIV sales growth (including Biktarvy) supports revenue expectations, while profitability risk may dominate near-term positioning.
Market read
Guidance and quarterly HIV sales beats provide a fresh catalyst for Gilead positioning, but the widened adjusted loss range tied to $12.4B in deal charges adds downside risk to earnings expectations.
What to watch
The article attributes HIV sales growth partly to higher prices and inventory dynamics, so traders may discount durability versus volume-led growth when modeling future margins.
Background
Gilead’s HIV franchise is centered on Biktarvy, and the company is also navigating US pricing negotiations under the Inflation Reduction Act.
Ticker impact
Gilead hiked its full-year product sales outlook and reported Q3 results, including an 18% jump in HIV sales and Biktarvy growth.
Shares likely face a mixed reaction, with upward sales guidance and Biktarvy demand offset by concerns around deal-related charges and the widened adjusted loss outlook.
The article provides both an upside guide (product sales raised) and a downside earnings signal (adjusted loss per share range widened higher) tied to large deal-related charges, creating two competing drivers for valuation and risk.
Market effects
Reinforces demand resilience in HIV prevention and the pricing framework under the Inflation Reduction Act, which can influence sentiment across large HIV franchises.
Limited direct regional spillover beyond US healthcare/biopharma sentiment from a major US-listed name’s guidance change.
US Medicare pricing mechanics for Biktarvy (effective 2028) may be a read-through for global pricing negotiations and payer dynamics in HIV markets.
Counterpoint
The raised sales outlook may not translate into improved profitability given the much larger deal-related charges and the widened adjusted loss per share range.
Key entities
- companyGilead Sciences
US-listed drugmaker reporting Q3 results, raising full-year product sales outlook, and updating adjusted loss per share guidance.
- productBiktarvy
Flagship HIV drug whose quarterly sales rose 10% and whose Medicare maximum fair price process is set to take effect in 2028.
- regulatorUS Centers for Medicare & Medicaid Services (CMS)
Completed the process setting a new maximum fair price for Biktarvy for Medicare purchases effective January 1, 2028.
